Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
Open Access
- 2 April 2020
- Vol. 70 (2), 379-+
- https://doi.org/10.1136/gutjnl-2019-320170
Abstract
Objective Systemic inflammation predisposes acutely decompensated (AD) cirrhosis to the development of acute-on-chronic liver failure (ACLF). Supportive treatment can improve AD patients, becoming recompensated. Little is known about the outcome of patients recompensated after AD. We hypothesise that different inflammasome activation is involved in ACLF development in compensated and recompensated patients. Design 249 patients with cirrhosis, divided into compensated and recompensated (previous AD), were followed prospectively for fatal ACLF development. Two external cohorts (n=327) (recompensation, AD and ACLF) were included. Inflammasome-driving interleukins (ILs), IL-1α (caspase-4/11-dependent) and IL-1β (caspase-1-dependent), were measured. In rats, bile duct ligation-induced cirrhosis and lipopolysaccharide exposition were used to induce AD and subsequent recompensation. IL-1α and IL-1β levels and upstream/downstream gene expression were measured. Results Patients developing ACLF showed higher baseline levels of ILs. Recompensated patients and patients with detectable ILs had higher rates of ACLF development than compensated patients. Baseline CLIF-C (European Foundation for the study of chronic liver failure consortium) AD, albumin and IL-1α were independent predictors of ACLF development in compensated and CLIF-C AD and IL-1β in recompensated patients. Compensated rats showed higher IL-1α gene expression and recompensated rats higher IL-1β levels with higher hepatic gene expression. Higher IL-1β detection rates in recompensated patients developing ACLF and higher IL-1α and IL-1β detection rates in patients with ACLF were confirmed in the two external cohorts. Conclusion Previous AD is an important risk factor for fatal ACLF development and possibly linked with inflammasome activation. Animal models confirmed the results showing a link between ACLF development and IL-1α in compensated cirrhosis and IL-1β in recompensated cirrhosis.Keywords
Funding Information
- Horizon 2020 Framework Programme (668031, 731875, 825694)
- Ernst und Berta Grimmke Stiftung (5/19)
- Fundación Cellex
- Deutsche Forschungsgemeinschaft (CRC 1382 A09, SFB 1177 C02, SFB 815 A5, SFB TRR57 P18)
This publication has 43 references indexed in Scilit:
- The Interleukin-1α Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of CytokinesFrontiers in Immunology, 2013
- The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cellsFrontiers in Immunology, 2012
- IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile InflammationThe Journal of Immunology, 2011
- Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosisJournal of Hepatology, 2010
- Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cellsJournal of Hepatology, 2010
- Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophagesBlood, 2009
- Origin and physiological roles of inflammationNature, 2008
- ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1β and IL-18 secretion in an autocrine wayProceedings of the National Academy of Sciences of the United States of America, 2008
- Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthaseJournal of Hepatology, 2007
- A model to predict survival in patients with end-stage liver diseaseJournal of Hepatology, 2001